Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma ...

BeiGene (NASDAQ:BGNE) announced Friday that the U.S. Food and Drug Administration (FDA) approved its cancer medicine Tevimbra ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today annou ...

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

The approval was based on data from the randomized, placebo-controlled, double-blind, phase 3 RATIONALE-305 trial.

The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum and ...

The Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr) in combination with platinum and ...

BeiGene (BGNE), a global oncology company that intends to change its name to BeOne Medicines, announced the U.S. FDA has approved Tevimbra in ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy to treat unresectable or metastatic, HER2-, PD-L1+ gastric or GEJ adenocarcinoma.

BeiGene has won approval from the US Food and Drug Administration for its PD-1 inhibitor Tevimbra (tislelizumab) in combination with chemotherapy to treat advanced gastric or gastroesophageal ...

New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA ...